By Chris WackArgenx shares were up 25% to $474.87 in premarket trading after the company said it and Zai Lab saw positive topline results from their study evaluating Vyvgart Hytrulo, or efgartigimod alfa and hyaluronidase-qvfc, in adults with chronic inflammatory demyelinating polyneuropathy. Zai Lab shares were up 10% to $30.49 in premarket trading. The companies said the study met its primary endpoint, demonstrating a significantly lower risk of relapse with Vyvgart Hytrulo compared with placebo. The most frequent treatment-related adverse event was injection site reactions, which occurred in a lower percentage of patients than previous Vyvgart Hytrulo trials. All injection site reactions were mild to moderate and resolved over time.

Source: Wall Street Journal July 17, 2023 14:29 UTC